Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis,Expert Review of Anti-infective Therapy

当前位置： X-MOL 学术 › Expert Rev. Anti Infect. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis
Expert Review of Anti-infective Therapy ( IF 4.2 ) Pub Date : 2021-09-29 , DOI: 10.1080/14787210.2021.1982695
Ronal Yosua Limen ₁ , Rudyanto Sedono ₁ , Adhrie Sugiarto ₁ , Timotius Ivan Hariyanto _{1,

2}

Affiliation

ABSTRACT

Background

Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of their ability in restraining immune response, yet the corroboration regarding their advantage is still unclear. This study sought to analyze the efficacy of JAK-inhibitors to ameliorate the outcomes of Covid-19 sufferer.

Research design and methods: Using specific keywords, we comprehensively go through the potential articles on ClinicalTrials.gov, Europe PMC, and PubMed sources until June 2^nd, 2021. All published studies on JAK-inhibitors and Covid-19 were collected.

Results

There were 14 studies with 4,363 Covid-19 patients contained in the meta-analysis. Based on our data, we suggested that JAK-inhibitors corresponded with increased recovery rate (RR 1.17; 95%CI: 1.01–1.36, p= 0.040, I² = 91%, random-effect modeling); shortened time to recovery (mean difference −0.96; 95%CI: −1.15, −0.77, p< 0.00001, I² = 28%, random-effect modeling); reduction of clinical deterioration risk (RR 0.66; 95%CI: 0.48–0.89, p= 0.008, I² = 57%, random-effect modeling); and reduction of Covid-19 mortality (RR 0.52; 95%CI: 0.36–0.76, p= 0.0006, I² = 33%, random-effect modeling).

Conclusions

This study propose that JAK-inhibitors perhaps provide advantageous effects on Covid-19 outcomes. JAK-inhibitors may be given during 1–2 weeks of disease to optimize its beneficial effects in halting the exaggerated immune response.

中文翻译：

Janus 激酶 (JAK) 抑制剂和 2019 年冠状病毒病 (Covid-19) 结果：系统评价和荟萃分析

抽象的

背景

目前，JAK 抑制剂因其抑制免疫反应的能力而被重新用于治疗 Covid-19，但其优势的证据仍不清楚。本研究旨在分析 JAK 抑制剂改善 Covid-19 患者预后的功效。

研究设计和方法：使用特定关键词，我们全面浏览了 ClinicalTrials.gov、Europe PMC 和 PubMed 来源上截至 2021 年 6 月 2^日的潜在文章。收集了所有已发表的有关 JAK 抑制剂和 Covid-19 的研究。

结果

荟萃分析包含 14 项研究，涉及 4,363 名 Covid-19 患者。根据我们的数据，我们认为 JAK 抑制剂与恢复率增加相对应（RR 1.17；95%CI：1.01–1.36， p = 0.040， I ² = 91%，随机效应模型）；恢复时间缩短（平均差 -0.96；95%CI：-1.15，-0.77， p < 0.00001， I ² = 28%，随机效应模型）；降低临床恶化风险（RR 0.66；95%CI：0.48–0.89， p = 0.008， I ² = 57%，随机效应模型）；并降低 Covid-19 死亡率（RR 0.52；95%CI：0.36–0.76， p = 0.0006， I ² = 33%，随机效应模型）。